Synonyms: faricimab-svoa | RG-7716 | RG7716 | RO-6867461 | RO6867461 | Vabysmo®
faricimab is an approved drug (EMA & FDA (2022))
Compound class:
Antibody
Comment: Faricimab is a bispecific monoclonal antibody that simultaneously binds to angiopoietin 2 (Ang2) and vascular endothelial growth factor A (VEGF-A) [3-4]. It is an angiogenesis inhibitor. The FcRn and FcγR binding sites of faricimab have been modified to disable its Fc‐mediated effector functions. Faricimab does not bind to Ang1 [4].
|
Selectivity at ligand targets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|